Serum CYFRA21-1 as a prognostic marker for patients with undifferentiated nasopharyngeal carcinoma

Biomarkers

Volumn 15, Issue 7, 2010, Pages 602-607

  Zhu, Wan Qi ^a   Yu, Jin Ming ^a   Sun, Xin Dong ^a   Xie, Peng ^a   Kong, Li ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

CEA; CYFRA21 1; Nasopharyngeal carcinoma; Prognosis; Undifferentiated

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PROGNOSIS;

ADULT; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CELL DIFFERENTIATION; FEMALE; HUMANS; KERATIN-19; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 77958614183     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2010.504309     Document Type: Article

References (29)

1. Bauch CT, Anonychuk AM, Van Efelterre T, Pham BZ, Merid MF. (2009). Incorporating herd immunity efects into cohort models of vaccine cost-efectiveness. Med Decis Making 29:557-69.
2. Blankenburg F, Hatz R, Nagel D, Ankerst D, Reinmiedl J, Gruber C, Seidel D, Stieber P. (2008). Preoperative CYFRA21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biol 29:272-7.
3. Cojocaru IM, Cojocaru M, Tanasescu R, Burcin C, Atanasiu AN, Mitu AC, Iliescu I, Dumitrescu L. (2008). Some clinico-immunological aspects in patients with ocular myasthenia gravis associated with infammatory bowel disease. Rom J Intern Med 46:165-8.
4. Dancey JE, Dodd LE, Ford R, Kaplan R, Mooney M, Rubinstein L, Schwartz LH, Shankar L, Therasse P. (2009). Recommendations for the assessment of progression in randomised cancer treatment trials. Eur J Cancer 45:281-9.
5. Deng YF, Chen P, Lin YZ, Le JZ, Wu XL, Yu MQ, Zhuang PY, Gao MH. (2003). Analytical and clinical evaluation of CYFRA 21-1 by elec-trochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol 117:190-4. (Pubitemid 36286643)
6. Deyasi SK, Aikat BK, Sengupta U, Sehgal S. (1974). Detection and localisation of carcinoembryonic antigen (CEA). Indian J Cancer 11:457-61.
7. Doweck I, Barak M, Uri N, Greenberg E. (2000). The prognostic value of the tumour marker CYFRA21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 83:1696-701. (Pubitemid 32001716)
8. Gkialas I, Papadopoulos G, Iordanidou L, Stathouros G, Tzavara C, Gregorakis A, Lykourinas M. (2008). Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma. Urology 72:1159-63.
9. Hofmann-Fazel A, Hofmann M, Gottschlich S, Maass JD, Rudert H, Maune S. (2003). CYFRA21-1 in diagnosis of distant metastases of head and neck carcinoma. Anticancer Res 23:917-20. (Pubitemid 36750895)
10. Ho S, Leung W T, Yuen J. (1996). Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy. Eur J Cancer B Oral Oncol 32B:377-80. (Pubitemid 27023564)
11. Jmal A, Boussen H, Abdennebi M, Gara S, Harzallah L, Gritli S, Ladgham A, Guemira F, Ghanem A. (2004). Contribution of serum CYFRA 21-1 in nasopharyngeal carcinoma in Tunisia. Bull Cancer 91:369-72. (Pubitemid 38662068)
12. Kandiloros D, Eleftheriadou A, Chalastras T, Kyriou L, Yiotakis I, Ferekidis E. (2006). Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck. Med Oncol 23:463-70. (Pubitemid 46252823)
13. Kremer A, Holdenrieder S, Stieber P, Wilkowski R, Nagel D, Seidel D. (2006). Nucleosomes in colorectal cancer patients during radio-chemotherapy. Tumour Biol 27:235-42. (Pubitemid 44260248)
14. Krishna SM, James S, Balaram P. (2006). Expression of VEGF as prog-nosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 115:85-90. (Pubitemid 41772484)
15. Laarman DA, van Kamp GJ, Balm AJ, Braakhuis BJ, Snow GB. (1991). Carcinoembryonic antigen and head and neck cancer. Clin Otolaryngol Allied Sci 16:182-6.
16. Leung S F, Lo YM, Chan AT, Johnson PJ. (2003). Disparity of sensitivities in detection of radiation-naive and postirradiation recurrent nasopharyngeal carcinoma of the undiferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2. Clin Cancer Res 9:3431-4.
17. Lin WY, Yen TC, Cheng KY, Wang SJ. (1998). The value of CYFRA21-1, a new tumor marker, in nasopharyngeal carcinoma. Neoplasma 45:21-4.
18. Makdissi FB, Machado LV, Oliveira AG, Benvenuti TT, Katayama ML, Brentani MM, Osório CA, Mourão Netto M, Lyra EC, Carvalho F, Góes JC, Folgueira MA. (2009). Expression of E-cadherin, Snail and Hakai in epithelial cells isolated from the primary tumor and from peritumoral tissue of invasive ductal breast carcinomas. Braz J Med Biol Res 42:1128-37.
19. Mrázová V, Mocák J, Varmusová E, Kavková D, Bednárová A. (2009). Use of multidimensional data analysis for prediction of lung malignity. J Pharm Biomed Anal 50:210-5.
20. Nart D, Ertan Y, Pala EE, Zeytunlu M, Zeytunlu M, Kilic M, Yilmaz F. (2008). Intrahepatic cholangiocarcinoma arising in chronic viral hepatitis-associated cirrhosis: two transplant cases. Transplant Proc 40:3813-15.
21. Nakao K, Mochiki M, Nibu K, Sugasawa M, Uozaki H. (2006). Analysis of prognostic factors of nasopharyngeal carcinoma: impact of in situ hybridization for Epstein-Barr virus encoded small RNA 1. Otolaryngol Head Neck Surg 134:639-45.
22. Sakao Y, Nakazono T, Sakuragi T, Natsuaki M, Itoh T. (2004). Predictive factors for survival in surgically resected clinical IA peripheral adenocarcinoma of the lung. Ann Torac Surg 77:1157-61. (Pubitemid 38452337)
23. Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, Inoue H, Kondo M, Mori Y, Tanaka E, Imamura M. (2005). Clinical signif-cance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 68:285-92. (Pubitemid 41158988)
24. Tsuchiya Y, Onda M, Miyashita M, Sasajima K. (1999). Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumor stage and prognosis of squamous cell carcinoma of the oesophagus. Med Oncol 16:31-7. (Pubitemid 29238379)
25. van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM, Elbers HR. (2000). Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117:374-9.
26. Wang LF, Chai CY, Kuo WR, Tai CF, Lee KW, Ho KY. (2006). Correlation between proliferating cell nuclear antigen and p53 protein expression and 5-year survival rate in nasopharyngeal carcinoma. Am J Otolaryngol 27:101-5.
27. Xi LF, Hughes JP, Edelstein ZR, Kiviat NB, Koutsky LA, Mao C, Ho J, Schifman M. (2009). Human papillomavirus (HPV) type 16 and type 18 DNA loads at baseline and persistence of type-specifc infection during a 2-year follow-up. J Infect Dis 200:1789-97.
28. Xie P, Yue JB, Fu Z, Feng R, Yu JM. (2010). Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol 21:1078-82.
29. Yamada H, Ishihara H, Kitagawa H, Kawabata Y, Itoyama S, Sugawara I. (1992). Preferential expression of immunoreactive fucosylceramide in adenocarcinoma of the lung. Cancer Res 52:4408-12.